GlobeNewswire Inc.··Spyre Therapeutics, Inc.Spyre's SPY001 Shows Promise in Ulcerative Colitis With Strong SKYLINE Trial Data
Spyre Therapeutics reports positive Phase 2 results for SPY001 in ulcerative colitis, meeting primary endpoints with significant histopathology improvements and favorable safety.
SYREulcerative colitisclinical remission